Cystic Fibrosis Clinical Trial
Official title:
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
This study will be performed at the University of Washington. Forty subjects with Cystic
Fibrosis will be enrolled, with 20 randomized into the usual care arm and 20 randomized into
the intervention arm. All subjects will be enrolled for 6 months and have 3 study visits.
One at baseline, midpoint, and final. The intervention arm subjects may have more study
visits depending on their respiratory symptoms.
The intervention arm subjects will perform home spirometry twice a week with a PiKo-6 hand
held spirometer. They will also have a home-based telemonitoring system connected to their
phone line. They will be prompted twice a week to answer questions regarding their health
via the telemonitor.
Subjects who are not able to utilize the home-based telemonitoring system will answer the
questions regarding their health via the internet from their home computer.
If the subject's spirometry falls by greater than 10% from baseline or the CF respiratory
symptoms change in 3 or more of the 8 respiratory symptoms captured by the telemonitor
questionnaire, the subject will be called by the research staff and clinically evaluated by
the study PIs within three days.
The usual care subjects will continue with their routine care at the University of
Washington CF Clinic.
The study design is a single center, randomized non-blinded controlled clinical trial
comparing usual care to a program of early identification and treatment of pulmonary
exacerbation in adults with CF. Forty subjects will be enrolled a at the University of
Washington with 20 subjects randomized into the usual care arm, and 20 randomized into the
intervention arm.
Usual care is defined as the regular quarterly CF visits with acute visits triggered by
calls from the patient to the clinic. Neither home assessment of spirometry or standardized
home symptom assessment are a component of usual care. Treatment of a pulmonary exacerbation
will be based on a standard protocol employing a standard definition and treatment regimen.
This study will employ current standardized CF pulmonary exacerbation orders used at the
University of Washington. Usual care arm subjects will have 3 study visits at baseline,
midpoint, and final, over a period of 6 months.
The early intervention protocol will employ twice a week assessment of home spirometry and
CF respiratory symptoms; we will employ a home based monitoring system from Philips called
the Philips Remote Patient Monitoring system (TeleStation). The home monitoring system is
connected to the patient's phone line; this system is currently used in clinical practice in
the care of patients with diabetes and heart failure.
Subjects who do not have a home phone line will answer the CF respiratory questions via the
internet from their home computer.
The home spirometry will be done using a PiKo-6 hand held spirometer up to 84 spirometry
values. If the subject's spirometry falls by greater than 10% from baseline or the CF
respiratory symptoms change in 3 or more of the 8 respiratory symptoms captured in the
questionnaire, the subject will be called by the research staff and clinically evaluated by
the study PIs within three days. This evaluation will include a history and physical exam
along with repeat spirometry at the clinic. The intervention arm subjects will have 3 study
visits at baseline, midpoint, and final, over a period of 6 months. They may have additional
study visits depending on their respiratory symptoms or exacerbations during the 6 month
study period.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |